{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:42:39Z","timestamp":1770990159474,"version":"3.50.1"},"reference-count":108,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2009,5,20]],"date-time":"2009-05-20T00:00:00Z","timestamp":1242777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,7,7]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>B cell-directed therapies are promising treatments for autoimmune disorders. Besides targeting CD20, newer B cell-directed therapies are in development that target other B cell surface molecules and differentiation factors. An increasing number of B cell-directed therapies are in development for the treatment of autoimmune disorders. Like rituximab, which is approved as a treatment for rheumatoid arthritis (RA), many of these newer agents deplete B cells or target pathways essential for B cell development and function; however, many questions remain about their optimal use in the clinic and about the role of B cells in disease pathogenesis. Other therapies besides rituximab that target CD20 are the furthest along in development. Besides targeting CD20, the newer B cell-directed therapies target CD22, CD19, CD40\u2013CD40L, B cell activating factor belonging to the TNF family (BAFF) and A proliferation-inducing ligand (APRIL). Rituximab is being tested in an ever-increasing number of autoimmune disorders and clinical studies of rituximab combined with other biological therapies are being pursued for the treatment of rheumatoid arthritis (RA). B cell-directed therapies are being tested in clinical trials for a variety of autoimmune disorders including RA, systemic lupus erythematosus (SLE), Sj\u00f6gren\u2019s syndrome, vasculitis, multiple sclerosis (MS), Graves' disease, idiopathic thrombocytopenia (ITP), the inflammatory myopathies (dermatomyositis and polymyositis) and the blistering skin diseases pemphigus and bullous pemphigoid. Despite the plethora of clinical studies related to B cell-directed therapies and wealth of new information from these trials, much still remains to be discovered about the pathophysiological role of B cells in autoimmune disorders.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2009.03979.x","type":"journal-article","created":{"date-parts":[[2009,5,20]],"date-time":"2009-05-20T11:52:23Z","timestamp":1242820343000},"page":"198-208","source":"Crossref","is-referenced-by-count":48,"title":["Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders"],"prefix":"10.1093","volume":"157","author":[{"given":"M C","family":"Levesque","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Rheumatology and Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,5,20]]},"reference":[{"key":"2021122708533106200_b1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.21525","article-title":"New prospects for autoimmune disease therapy: B cells on deathwatch","volume":"54","author":"St Clair","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b2","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/art.22020","article-title":"Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms","volume":"54","author":"Silverman","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrd2085","article-title":"B cells move to centre stage: novel opportunities for autoimmune disease treatment","volume":"5","author":"Browning","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2021122708533106200_b4","first-page":"210","article-title":"Emerging therapeutics for rheumatoid arthritis","volume":"66","author":"Bingham","year":"2008","journal-title":"Bull NYU Hosp Joint Dis"},{"key":"2021122708533106200_b5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/BOR.0b013e3282f5e08d","article-title":"New approaches of B-cell-directed therapy: beyond rituximab","volume":"20","author":"Dorner","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"2021122708533106200_b6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2249.2009.03977.x","article-title":"B cell-directed therapy for autoimmune diseases","volume":"157","author":"Hu","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"2021122708533106200_b7","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b8","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b9","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nri1838","article-title":"B-cell targeting in rheumatoid arthritis and other autoimmune diseases","volume":"6","author":"Edwards","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"2021122708533106200_b10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2006.03.010","article-title":"B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks?","volume":"121","author":"Stohl","year":"2006","journal-title":"Clin Immunol"},{"key":"2021122708533106200_b11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1146\/annurev.immunol.24.021605.090517","article-title":"B cell immunobiology in disease: evolving concepts from the clinic","volume":"24","author":"Martin","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"2021122708533106200_b12","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1038\/sj.onc.1210376","article-title":"Rituximab therapy in malignant lymphoma","volume":"26","author":"Coiffier","year":"2007","journal-title":"Oncogene"},{"key":"2021122708533106200_b13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.hoc.2004.04.008","article-title":"Antibody therapy for chronic lymphocytic leukemia: a promising new modality","volume":"18","author":"Lin","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"2021122708533106200_b14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2249.2009.03978.x","article-title":"The pathogenic role of B cells in autoantibody-associated autoimmune diseases \u2013 lessons from B cell-depletion therapy","volume":"157","author":"Leandro","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"2021122708533106200_b15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: a regulator of cell-cycle progression of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol Today"},{"key":"2021122708533106200_b16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clim.2005.08.006","article-title":"The therapeutic potential of anti-CD20 \u2018what do B-cells do?\u2019","volume":"117","author":"Eisenberg","year":"2005","journal-title":"Clin Immunol"},{"key":"2021122708533106200_b17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaci.2007.11.030","article-title":"B cell-directed therapies for autoimmune disease and correlates of disease response and relapse","volume":"121","author":"Levesque","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"2021122708533106200_b18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/cyto.990140212","article-title":"CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes","volume":"14","author":"Hultin","year":"1993","journal-title":"Cytometry"},{"key":"2021122708533106200_b19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/ajcp\/102.4.483","article-title":"CD20+ T-cell lymphoma. Neoplastic transformation of a normal T-cell subset","volume":"102","author":"Quintanilla-Martinez","year":"1994","journal-title":"Am J Clin Pathol"},{"key":"2021122708533106200_b20","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.4049\/jimmunol.171.3.1581","article-title":"Complement activation determines the therapeutic activity of rituximab in vivo","volume":"171","author":"Di Gaetano","year":"2003","journal-title":"J Immunol"},{"key":"2021122708533106200_b21","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO;2-C","article-title":"Serum sickness secondary to treatment with the murine\u2013human chimeric antibody IDEC-C2B8 (rituximab)","volume":"44","author":"D'Arcy","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b22","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1046\/j.1365-2141.2001.03166.x","article-title":"Complement activation plays a key role in the side-effects of rituximab treatment","volume":"115","author":"Van Der Kolk","year":"2001","journal-title":"Br J Haematol"},{"key":"2021122708533106200_b23","first-page":"250","article-title":"Monoclonal antibodies, immunogenicity, and associated infusion reactions","volume":"72","author":"Cheifetz","year":"2005","journal-title":"Mount Sinai J Med"},{"key":"2021122708533106200_b24","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2007-02-074716","article-title":"NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement","volume":"111","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"2021122708533106200_b25","first-page":"430","article-title":"Serum sickness following treatment with rituximab","volume":"34","author":"Todd","year":"2007","journal-title":"J Rheumatol"},{"key":"2021122708533106200_b26","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","article-title":"Systematic review: agranulocytosis induced by nonchemotherapy drugs","volume":"146","author":"Andersohn","year":"2007","journal-title":"Ann Intern Med"},{"key":"2021122708533106200_b27","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/annonc\/mdl393","article-title":"A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study","volume":"18","author":"Nitta","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122708533106200_b28","first-page":"3","article-title":"Rituxan warning","volume":"41","year":"2007","journal-title":"FDA Consum"},{"key":"2021122708533106200_b29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"key":"2021122708533106200_b30","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122708533106200_b31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2021122708533106200_b32","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b33","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/rheumatology\/kei080","article-title":"B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients","volume":"44","author":"Leandro","year":"2005","journal-title":"Rheumatology"},{"key":"2021122708533106200_b34","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1002\/art.21351","article-title":"B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus","volume":"52","author":"Marks","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b35","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2021122708533106200_b36","first-page":"L12","article-title":"Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II\/III study EXPLORER","volume":"58","author":"Merrill","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b37","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","article-title":"Immune thrombocytopenic purpura","volume":"346","author":"Cines","year":"2002","journal-title":"N Engl J Med"},{"key":"2021122708533106200_b38","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2141.2006.06024.x","article-title":"The pathogenesis of immune thrombocytopaenic purpura","volume":"133","author":"Cooper","year":"2006","journal-title":"Br J Haematol"},{"key":"2021122708533106200_b39","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood-2008-01-131029","article-title":"Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study","volume":"112","author":"Godeau","year":"2008","journal-title":"Blood"},{"key":"2021122708533106200_b40","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122708533106200_b41","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122708533106200_b42","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2165\/00003495-200666150-00004","article-title":"B-cell-targeted therapy for systemic lupus erythematosus","volume":"66","author":"Sabahi","year":"2006","journal-title":"Drugs"},{"key":"2021122708533106200_b43","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sj\u00f6gren\u2019s syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b44","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sj\u00f6gren\u2019s syndrome","volume":"66","author":"Seror","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2021122708533106200_b45","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/art.22536","article-title":"Improvement of Sj\u00f6gren\u2019s syndrome after two infusions of rituximab (anti-CD20)","volume":"57","author":"Devauchelle-Pensec","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b46","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2021122708533106200_b47","first-page":"713","article-title":"Rituximab treatment in primary Sj\u00f6gren\u2019s syndrome: A double-blind placebo controlled trial","volume":"58","author":"Meijer","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b48","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2008.092601","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment","volume":"68","author":"Meijer","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2021122708533106200_b49","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b50","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/ard.2005.045898","article-title":"Rituximab in the treatment of antisynthetase syndrome","volume":"65","author":"Brulhart","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2021122708533106200_b51","first-page":"1021","article-title":"Rituximab as therapy for refractory polymyositis and dermatomyositis","volume":"33","author":"Noss","year":"2006","journal-title":"J Rheumatol"},{"key":"2021122708533106200_b52","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","article-title":"A pilot trial of rituximab in the treatment of patients with dermatomyositis","volume":"143","author":"Chung","year":"2007","journal-title":"Arch Dermatol"},{"key":"2021122708533106200_b53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02325","article-title":"Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study","volume":"156","author":"Salvi","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"2021122708533106200_b54","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1210\/jc.2006-2388","article-title":"B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study","volume":"92","author":"El Fassi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122708533106200_b55","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1530\/EJE-08-0084","article-title":"Rituximab in relapsing Graves' disease, a phase II study","volume":"159","author":"Heemstra","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"2021122708533106200_b56","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ajh.20169","article-title":"Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma","volume":"77","author":"Gajra","year":"2004","journal-title":"Am J Hematol"},{"key":"2021122708533106200_b57","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1067\/S0022-3476(03)00300-7","article-title":"Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report","volume":"143","author":"Wylam","year":"2003","journal-title":"J Pediatr"},{"key":"2021122708533106200_b58","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","article-title":"Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab","volume":"33","author":"Hain","year":"2006","journal-title":"Muscle Nerve"},{"key":"2021122708533106200_b59","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients","volume":"201\u2013202","author":"Illa","year":"2008","journal-title":"J Neuroimmunol"},{"key":"2021122708533106200_b60","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial","volume":"63","author":"Bar-Or","year":"2008","journal-title":"Ann Neurol"},{"key":"2021122708533106200_b61","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122708533106200_b62","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","article-title":"Response of Wegener\u2019s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy","volume":"44","author":"Specks","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b63","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","article-title":"Rituximab for refractory Wegener\u2019s granulomatosis: report of a prospective, open-label pilot trial","volume":"173","author":"Keogh","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2021122708533106200_b64","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/02813430510015269","article-title":"Anti-CD20 therapy of treatment-resistant Wegener\u2019s granulomatosis: favourable but temporary response","volume":"34","author":"Omdal","year":"2005","journal-title":"Scand J Rheumatol"},{"key":"2021122708533106200_b65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ndt\/gfn430","article-title":"Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients","volume":"24","author":"Lovric","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2021122708533106200_b66","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1002\/art.22811","article-title":"Development of psoriasis after B cell depletion with rituximab","volume":"56","author":"Dass","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b67","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2007.080929","article-title":"Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma","volume":"67","author":"Mielke","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2021122708533106200_b68","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1182\/blood-2008-04-149161","article-title":"Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation","volume":"112","author":"Beers","year":"2008","journal-title":"Blood"},{"key":"2021122708533106200_b69","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2967\/jnumed.107.043489","article-title":"Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice","volume":"48","author":"Jacene","year":"2007","journal-title":"J Nucl Med"},{"key":"2021122708533106200_b70","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","article-title":"First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial","volume":"111","author":"Hagenbeek","year":"2008","journal-title":"Blood"},{"key":"2021122708533106200_b71","doi-asserted-by":"crossref","first-page":"822","DOI":"10.4049\/jimmunol.181.1.822","article-title":"Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis","volume":"181","author":"Beum","year":"2008","journal-title":"J Immunol"},{"key":"2021122708533106200_b72","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/art.23732","article-title":"Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I\/II randomized, blinded, placebo-controlled, dose-ranging study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b73","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2008-07-168146","article-title":"Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody","volume":"113","author":"Goldenberg","year":"2009","journal-title":"Blood"},{"key":"2021122708533106200_b74","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1\u20132 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"key":"2021122708533106200_b75","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMra0708875","article-title":"Monoclonal antibody therapy for B-cell non-Hodgkin\u2019s lymphoma","volume":"359","author":"Cheson","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122708533106200_b76","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1158\/1078-0432.CCR-03-0493","article-title":"Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin\u2019s lymphoma","volume":"10","author":"Stein","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2021122708533106200_b77","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/nbt1008-1053","article-title":"CD20 blockers eye crowded rheumatology market","volume":"26","author":"Mack","year":"2008","journal-title":"Nat Biotechnol"},{"key":"2021122708533106200_b78","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/ar1942","article-title":"Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus","volume":"8","author":"Dorner","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"2021122708533106200_b79","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/ard.2007.075762","article-title":"Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls","volume":"67","author":"Jacobi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2021122708533106200_b80","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nri844","article-title":"BAFF: a fundamental survival factor for B cells","volume":"2","author":"Mackay","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"2021122708533106200_b81","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.0105-2896.2005.00219.x","article-title":"The role of BAFF in immune function and implications for autoimmunity","volume":"204","author":"Kalled","year":"2005","journal-title":"Immunol Rev"},{"key":"2021122708533106200_b82","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.173.2.807","article-title":"B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells","volume":"173","author":"Ng","year":"2004","journal-title":"J Immunol"},{"key":"2021122708533106200_b83","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd1982","article-title":"An APRIL to remember: novel TNF ligands as therapeutic targets","volume":"5","author":"Dillon","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2021122708533106200_b84","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/eji.200636914","article-title":"To switch or not to switch \u2013 the opposing roles of TACI in terminal B cell differentiation","volume":"37","author":"Salzer","year":"2007","journal-title":"Eur J Immunol"},{"key":"2021122708533106200_b85","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J Exp Med"},{"key":"2021122708533106200_b86","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1172\/JCI0214121","article-title":"Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sj\u00f6gren\u2019s syndrome","volume":"109","author":"Groom","year":"2002","journal-title":"J Clin Invest"},{"key":"2021122708533106200_b87","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S","article-title":"Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases","volume":"44","author":"Cheema","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b88","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4049\/jimmunol.166.1.6","article-title":"Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus","volume":"166","author":"Zhang","year":"2001","journal-title":"J Immunol"},{"key":"2021122708533106200_b89","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.4049\/jimmunol.169.8.4314","article-title":"BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases","volume":"169","author":"Roschke","year":"2002","journal-title":"J Immunol"},{"key":"2021122708533106200_b90","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.21650","article-title":"Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b91","doi-asserted-by":"crossref","first-page":"R167","DOI":"10.1186\/ar2076","article-title":"Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"8","author":"Vallerskog","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"2021122708533106200_b92","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2021122708533106200_b93","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1084\/jem.192.7.953","article-title":"Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response","volume":"192","author":"Do","year":"2000","journal-title":"J Exp Med"},{"key":"2021122708533106200_b94","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.4049\/jimmunol.175.9.6143","article-title":"Innate immunity and human B cell clonal expansion: effects on the recirculating B2 subpopulation","volume":"175","author":"Mongini","year":"2005","journal-title":"J Immunol"},{"key":"2021122708533106200_b95","first-page":"S780","article-title":"Changes in circulating B-cell counts, autoantibody levels and immunoglobulins that associate with therapeutic responsiveness in SLE to BLyS protein antagonism by belimumab","volume":"54","author":"Stohl","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b96","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/toxsci\/kfj148","article-title":"Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects","volume":"91","author":"Halpern","year":"2006","journal-title":"Toxicol Sci"},{"issue":"2","key":"2021122708533106200_b97","first-page":"56","article-title":"Novel combined response endpoint shows that belimumab (fully human monoclonal antibody to B-lymphocyte stimulator [BLYS]) improves or stabilizes SLE disease activity in a phase 2 trial","volume":"66","author":"Ginzler","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"II","key":"2021122708533106200_b98","first-page":"53","article-title":"Belimumab (fully human monoclonal antibody to BLyS) improved or stabilized systemic lupus erythematosus (SLE) disease activity and reduced flare rate during 3 years of therapy","volume":"67","author":"Furie","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"II","key":"2021122708533106200_b99","first-page":"217","article-title":"Progressive normalization of autoantibody, immunoglobulin, and complement levels over 3 years of belimumab (fully human monoclonal antibody to BLyS) therapy in systemic lupus erythematosus (SLE) patients","volume":"67","author":"Chatham","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2021122708533106200_b100","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1002\/art.23047","article-title":"Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial","volume":"56","author":"Dall'Era","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b101","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/art.23178","article-title":"Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study","volume":"58","author":"Tak","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b102","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/08916930400002386","article-title":"The role of CD40\u2013CD154 interactions in autoimmunity and the benefit of disrupting this pathway","volume":"37","author":"Toubi","year":"2004","journal-title":"Autoimmunity"},{"key":"2021122708533106200_b103","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1385\/IR:24:3:311","article-title":"CD40:CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes","volume":"24","author":"Bhushan","year":"2001","journal-title":"Immunol Res"},{"key":"2021122708533106200_b104","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2008.07039.x","article-title":"The effect of anti-CD40 ligand in immune thrombocytopenic purpura","volume":"141","author":"Patel","year":"2008","journal-title":"Br J Haematol"},{"key":"2021122708533106200_b105","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/art.10856","article-title":"A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b106","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/art.10681","article-title":"Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Kalunian","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2021122708533106200_b107","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1172\/JCI200319301","article-title":"Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154\u2013CD40 interactions","volume":"112","author":"Grammer","year":"2003","journal-title":"J Clin Invest"},{"key":"2021122708533106200_b108","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.molimm.2007.08.006","article-title":"Platelet pro-aggregatory effects of CD40L monoclonal antibody","volume":"45","author":"Mirabet","year":"2008","journal-title":"Mol Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2009.03979.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/157\/2\/198\/41926788\/j.1365-2249.2009.03979.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/157\/2\/198\/41926788\/j.1365-2249.2009.03979.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:22:48Z","timestamp":1641054168000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/157\/2\/198\/6438852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,20]]},"references-count":108,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2009,5,20]]},"published-print":{"date-parts":[[2009,7,7]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2009.03979.x","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2009,8]]},"published":{"date-parts":[[2009,5,20]]}}}